Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Mifepristone - VGX Pharmaceuticals

X
Drug Profile

Mifepristone - VGX Pharmaceuticals

Alternative Names: PICTOVIR; VGX-410; VGX-410C

Latest Information Update: 11 Dec 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator VGX Pharmaceuticals
  • Class Abortifacients; Antidementias; Antidepressants; Antiglaucomas; Antineoplastics; Antiprogestogens; Antipsychotics; Antivirals; Dimethylamines; Estrenes; Eye disorder therapies; Obesity therapies; Oral contraceptives; Small molecules; Smoking cessation therapies
  • Mechanism of Action Glucocorticoid receptor antagonists; Hepatitis C internal ribosome entry site inhibitors; HIV pre-integration complex translocation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Hepatitis C; HIV infections

Most Recent Events

  • 02 Sep 2007 VGX Pharmaceuticals completes enrolment in the VT003 trial for Hepatitis C virus infections in the US
  • 21 Feb 2007 VGX 410 licensed to VGX International to sell and market in Asia and other developing regions, including Africa
  • 17 Oct 2006 Data presented at the 46th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC-2006) have been added to the adverse events and Viral Infections therapeutic trials sections
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top